Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children a doublie-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial

Next Previous
Search
Trial Profile

Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children a doublie-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors BIAL - Portela C S.A.

    • Most Recent Events

    • 28 Jun 2022 Results assessing cognitive adverse events of adjunctive eslicarbazepine acetate in children with focal seizures by collecting safety data from BIA-2093-208 and BIA-2093-305, presented at the 8th Congress of the European Academy of Neurology.
    • 08 Dec 2020 Results of 3 years of post-marketing experience vs. clinical trials presented at the 74th Annual Meeting of the American Epilepsy Society
    • 01 May 2020 Results (n=514) of pooled analysis of two open label extension studies (2093-208 and 2093-305) assessing long-term safety and tolerability of adjunctive eslicarbazepine acetate for 1-year and post-1-year, presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top